Thiopurine S-methyltransferase activity in Nigerians: phenotypes and activity reference values

Ayorinde Adehin1,2* and Oluseye O. Bolaji1

Abstract

Objectives: This study assessed the activity of thiopurine S-methyltransferase (TPMT) in Nigerians with a view to providing data on susceptibility to thiopurine toxicity, and as well generate reference activity values for clinical use.

Results: TPMT activity, expressed as the amount of 6MMP in ng/mL after 1 h incubation at 37 °C per haemoglobin (U/g Hb), varied between 2.34 and 63.50 U/g Hb in the study population. Poor metabolic phenotypes, characterised by an activity values below 8.41 U/g Hb, were observed in 20% of the study subjects. Intermediate metabolizers had activity values between 8.41 and 16.13 U/g Hb. Fast and very fast metabolizers were characterised by activity values of 16.20–56.22 and > 56.22 U/g Hb, respectively. These findings suggest that a potentially huge discordance between TPMT phenotype and genotype exist in Nigerians, and emphasizes the superiority of a prior determination of TPMT metabolic phenotype in ensuring the safety of thiopurine drug administration in the population.

Keywords: TPMT, Metabolic phenotypes, Thiopurine toxicity, Nigerians

Introduction

Thiopurine S-methyltransferase (TPMT) is a cytosolic enzyme that S-methylates heterocyclic and aromatic sulfhydryl compounds, and has been found to exhibit varied levels of activity in tissues, a phenomenon largely due to polymorphisms in its gene [1]. Inheritance is autosomal codominant [2] and the various populations studied to date have shown marked interindividual variation in enzyme activity.

TPMT plays a significant role in the biotransformation of clinically important thiopurine drugs used in the management of leukaemia, inflammatory bowel diseases (IBD), rheumatic diseases and dermatological conditions. These drugs are also used as immunosuppressants in the aftermath of organ transplant [3]. Thiopurines are metabolized to generate cytotoxic thioguanine nucleotides (e.g. 6-TGN) whose incorporation into nucleic acid materials form the basis of their immunosuppressive properties [4]. TPMT, however, inactivates thiopurines and functional polymorphisms in its gene can potentially alter the balance of this metabolic pathway. Haematological toxicity or altered antitumor effectiveness are the usual results of the accumulation of cytotoxic thioguanine nucleotides in instances of impaired thiopurine metabolism by TPMT [3, 5].

Genotyping remains an unambiguous method of detecting non-functional TPMT alleles with relatively high genotype-to-phenotype correlation of over 67% from some studies [5]. However, some non-genetic factors and genetic variation in the regulatory region of the TPMT gene [6] are known to alter phenotypes. This, hence, emphasizes the importance of phenotype determination in the precise classification of the TPMT metabolic status of individuals.

The present study, the first in a Nigerian population, thus aims to give information on the likely TPMT metabolic phenotypes and as well provide clinically useful reference activity values for the routine assessment of susceptibility to thiopurine toxicity.
Main text

Methods

One hundred healthy, unrelated adult subjects composed of 87 males and 13 females who were nonsmokers, were recruited. Ninety-three of these volunteers were from the Yoruba ethnic group while the other 8 were Igbo. The study population had a mean age ± SD of 28.78 ± 3.98 years. All subjects had never been on thiopurine drugs, and were also not on any form of therapy in at least 2 months preceding the study. Each volunteer provided 5 mL of whole blood which was collected in heparinized tubes. Erythrocytes prepared from the collected blood samples were lysed for haemolysates and incubated with 6-mercaptopurine (6MP) in the presence of S-adenosylmethionine (SAM) to assess TPMT activity via its production of 6-methylmercaptopurine (6MMP) as earlier described by Oselin et al. [6].

A validated analytical method using a HPLC (1100 series from Agilent Technologies, Palm Alto, USA) device fitted with a quaternary pump and a Diode array UV detector was employed. Samples were injected through a Rheodyne model 7725i valve (Cotati, California; USA) fitted with a 20 μL loop, and analytes were resolved with a reverse phase C18 Zorbax Eclipse XDB column (4 μm, 125 × 4.6 mm i.d.; Agilent technologies, Palm Alto, USA). Separation was achieved with a mobile phase composed of sodium dihydrogen phosphate buffer (0.01 M, pH 2.68) and acetonitrile in a gradient (Table 1) at 27 °C with eluate monitoring at 297 nm.

Haemoglobin content of the hemolysate was quantified using a colorimetric cyanmethemoglobin method. Haemoglobin-normalized TMPT activity values, computed as the amount of 6MMP in ng/mL after 1 h incubation at 37 °C per haemoglobin (U/g Hb), were subsequently generated. A Rosin–Rammler–Sperling–Weibull (RRSW) distribution analysis [7] was applied to log-transformed normalized values in order to identify breakpoints needed to describe prevalent phenotypic subgroups in the study population. Subgroups were described by the equation: $F(N) = 1 - \exp \left[ - \frac{X}{\alpha} \right]^\beta$, where $F(N)$ was the cumulative frequency at a particular log-transformed TPMT activity value ‘X’, while α and β were the scale and slope parameters, respectively. Initial breakpoints were arbitrarily chosen after data inspection, and $F(N)$ adjusted until β assumed a Gaussian distribution (judged by values between 3.5 and 4.5). The best distribution from several iterations within each subgroup was assessed and chosen based on a goodness of fit analysis using the $\chi^2$ test.

### Results

All analytes were resolved in 6.5 min with the retention times for 6MP, SAM and 6MMP being 2.4, 4.1 and 5.4 min, respectively. Assay recovery, studied between 5 and 250 ng/mL, was > 83%, while the coefficients of variation for intra- and inter-assay imprecision were < 3%. TPMT activity values varied between 4.88 and 158.85 ng/mL/h, and the corresponding haemoglobin-normalized activity values ranged between 2.34 and 63.50 U/g Hb. Null TPMT activity was recorded in two subjects. The presence of TPMT metabolic phenotypes was evidenced in the preliminary frequency distribution histogram plot of the population data (Fig. 1). Thereafter, two RRSW-functions defining breakpoints at 8.41 and 16.13 U/g Hb were derived after analysis (Fig. 2). By inference, the metabolic phenotypes identified comprised poor (< 8.41 U/g Hb, 20%), intermediate (8.41–16.13 U/g Hb, 14%) and fast (16.20–56.22 U/g Hb, 61%) metabolizers. The Weibull distribution defined by the second RRSW-function, with a breakpoint at 16.13 U/g Hb, only assumed a Gaussian distribution after the exclusion of activity values > 56.23 U/g Hb. This, hence, necessitated the inclusion of a fourth group, observed at a frequency of 5%, comprising individuals with marginally faster TPMT metabolic phenotype.

### Discussion

Genetic polymorphism in the TPMT gene with functional consequences has been reported as a major cause of the wide interindividual differences observed in TPMT activity. This has been used to explain variations in the metabolism, toxicity, and therapeutic efficacy of thiopurine drugs. It also known that TPMT activity vary over time in relation to continued administration of thiopurines and patient clinical condition [1, 8]. The present study assessed TPMT metabolic phenotypes in Nigerians and observed a much higher frequency (20%) of poor metabolizers than had been reported in other populations such as Italian-Caucasians (0.1%), Brazilians (0.3%), and German-Caucasians (0.6%) where phenotypes had been predicted using TPMT genotypes [9–11].

---

**Table 1** Gradient table for the HPLC analysis

| Time (min) | Acetonitrile (%) | Phosphate buffer (%) | Flow rate (mL/min) |
|------------|------------------|----------------------|--------------------|
| 0.00       | 2                | 98                   | 1.2                |
| 2.00       | 2                | 98                   | 1.2                |
| 2.50       | 10               | 90                   | 1.5                |
| 6.00       | 10               | 90                   | 1.5                |
| 6.05       | 2                | 98                   | 1.2                |
Interestingly, a recent study in Nigerians [12] which detected only the TPMT*3C allele found just one heterozygous individual in all 180 subjects studied. This would have suggested an estimated 0.6% poor metabolizers, thus emphasizing the pitfall in the prediction of TPMT metabolic phenotypes solely from genetic data for this population. A similar phenotype–genotype disparity has also been reported in Argentines [13] who were identified as intermediate metabolizers from phenotypic data but with only 12 of 21 such individuals being carriers of a copy of the generally assessed defective TPMT allele.

While the high frequency of poor metabolizers in the present study may not be explainable by projections of documented genetic data on some TPMT alleles in Nigerians, potential reasons may lie in other factors such as promoter polymorphisms [14], variable number of tandem repeats in the promoter region of TPMT [15, 16], and new/unstudied mutations in the TPMT gene. It is, hence, likely, these other genetic factors highlighted might have more significant roles in the determination of TPMT metabolic phenotypes for this population. This is quite possible because non-genetic modulators of TPMT activity (such as long period of thiopurine use, TPMT inhibitor-drug like as allopurinol, frusemide and naproxen [17, 18] and other unidentified factors) could not have interfered with the in vitro assay of TPMT activity as implemented in the present study.

Since individuals with very low or undetectable levels of TPMT activity are known to develop severe myelosuppression [19] when treated with standard doses of thiopurines, complete reliance on TPMT genetic data may not be sufficient, especially among Nigerian users of thiopurine drugs. Moreover, individuals with poor TPMT metabolic phenotypes are preferably not administered thiopurines, and if given, very low doses in the region of less than 10% of the standard doses have been recommended [20]. It is, however, worth stating that although thiopurine toxicity resulting from its altered metabolism has been significantly correlated with TPMT activity, later studies have also identified the roles of inosine triphosphatase (ITPA) [21] and Nudix Hydrolase 15 (NUDT15) [22] in predicting such toxicities.

The present study also identified intermediate metabolizers, with lesser risk of adverse events, for whom thiopurine therapy may be better optimized if properly classified prior to treatment. For example, a study by Gardiner et al. [23] in IBD patients suggested that intermediate TPMT metabolizers might benefit more from a threelfold reduction in standard thiopurine doses needed to achieve therapeutic 6-TGN concentrations of ‘> 235 pmol’ per ‘8 × 10⁶ RBCs’. Marginally-higher TPMT activity, seen in some individuals in the present study, had been reported in other populations as well but with no identified genetic/non-genetic causes.

![Figure 1](image-url)  
**Fig. 1** A frequency distribution histogram showing thiopurine S-methyltransferase activity, TPMT, activity values for 100 healthy, unrelated Nigerian subjects. U/g Hb: ‘unit per gram haemoglobin’ which is the amount of 6-methylmercaptopurine in ng/mL generated after a 1-h incubation at 37 °C per haemoglobin content.
Conclusion
This study suggests that more Nigerians than projected may be at the risk of thiopurine induced adverse events, and thus underscores the need for proper phenotypic classification of recipients of clinically relevant TPMT-substrate drugs prior to commencement of therapy.

Limitations
A limitation of the present study is the absence of genetic data on the major functional TPMT variants that are prevalent in Africans. This, in addition to data on polymorphisms in the TPMT gene promoter region and/or variable number of tandem repeats, would have provided more insight into the likely reasons for the high number of poor metabolizers observed in the population.

Abbreviations
TPMT: thiopurine S-methyltransferase; IBD: inflammatory bowel disease; 6-TGN: 6-thioguanine nucleotide; 6MP: 6-mercaptopurine; SAM: S-adenosylmethionine; 6MMP: 6-methylmercaptopurine; RRSW: Rosin–Rammler–Sperling–Weibull; ITPA: inosine triphosphatase; NUOT15: Nudix Hydrolase 15; RBC: red blood cells.

Authors’ contributions
AA and OOB designed the study. AA generated experimental data. OOB and AA analysed the data generated and prepared the manuscript. Both authors read and approved the final manuscript.

Author details
1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. 2 Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong Province, China.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication
Not applicable.
The study was not funded.

Funding
The study was not funded.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 6 January 2018  Accepted: 6 February 2018  Published online: 14 February 2018

References
1. van Egmond R, Barclay ML, Chin PK, Sies CW, Florkowski CM. Biological variation of thiopurine methyltransferase enzyme activity: when has a significant change taken place? Ann Clin Biochem. 2013;50:473–8.
2. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of thiopurine S-methyltransferase in African-Americans. Hum Mol Genet. 1999;8:371–6.
3. Ramsey LB, Janke LJ, Edick MJ, Cheng C, Williams RT, Sherr CJ, et al. Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. Pharmacogenomics. 2014;24:263–71.
4. Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment, a pharmacogenomic test whose time has come. J Clin Pathol. 2010;63:286–95.
5. Ford LT, Kampinis P, Berg J. Thiopurine S-methyltransferase genotype–phenotype concordance used as a quality assurance tool to help control the phenotype assay. Ann Clin Biochem. 2009;46:152–4.
6. Oselin K, Anier K, Tamr M, Kallassal K, Mæerg U. Determination of thiopurine S-methyltransferase (TPMT) activity by comparing various normalization factors: reference values for Estonian population using HPLC–UV assay. J Chromatogr B. 2006;834:77–83.
7. Jack DB. Statistical analysis of polymorphic drug metabolism data using the Rosin-Rammler-Sperling-Weibull distribution. Eur J Clin Pharmacol. 1983;25:443–8.
8. Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol. 2014;77:704–14.
9. Marcelo R, Ana S, Guilherme S. Thiopurine methyltransferase phenotypes and genotypes in Brazilians. Pharmacogenetics. 2003;13:371–3.
10. Serpe L, Calvo PL, Muntoni E, D’Antico S, Giaccone M, Avagnina A, et al. Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity. Pharmacogenomics. 2009;10:1753–65.
11. Schaefferle E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype–genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics. 2004;14:407–17.
12. Adehin A, Bolaji O, Kennedy MA, Adeagbo BA. Allele frequencies of thiopurine S-methyltransferase (TPMT) variants in the Nigerian population. Pol Ann Med. 2017;24:144–7.
13. Lardovere LE, de Kremer RD, Lambooy LH, De Abreu RA. Genetic polymorphism of thiopurine S-methyltransferase in Argentina. Ann Clin Biochem. 2003;40:388–93.
14. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus: implications for clinical pharmacogenomics. Pharmacogenomics. 2002;3:89–98.
15. Yan L, Zhang S, Effif B, Szumlanski CL, Powers M, O’Brien J, et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype–phenotype correlation analysis. Clin Pharmacol Ther. 2000;68:210–9.
16. Alves S, Amorim A, Ferreira F, Prata MJ. Influence of the variable number of tandem repeats in promoter region of the thiopurine methyltransferase gene on the enzymatic activity. Clin Pharmacol Ther. 2001;70:165–74.
17. Lennard L. TPMT in the treatment of Crohn’s disease with azathioprine. Gut. 2002;51:143–6.
18. Oselin K, Anier K. Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti-inflammatory drugs in vitro: a mechanism for possible drug interactions. Drug Metab Dispos. 2007;35:1452–4.
19. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011;89:387–91.
20. Gardiner SJ, Gearry RB, Barclay ML, Begg EJ. Two cases of thiopurine methyltransferase (TPMT) deficiency—a lucky save and a near miss with azathioprine. Br J Clin Pharmacol. 2006;62:473–6.
21. Skrzypczak-Zielinska M, Borun P, Bartkowiak-Kaczmarek A, Zakenska-Banaszak O, Walczak M, Dobrowolska A, et al. A simple method for TPMT and ITPA genotyping using multiplex HRMA for patients treated with thiouprine drugs. Mol Diagn Ther. 2016;20:493–9.
22. Moriyma T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48:567–73.
23. Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol. 2008;6:654–60.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit